Cue Biopharma Ownership 2024 | Who Owns Cue Biopharma Now?
Institutional Ownership
4.76%
Insider Ownership
0.68%
Retail Ownership
94.56%
Institutional Holders
33.00
Cue Biopharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BLEICHROEDER LP | 5.78% | 1.06% | 2,861,606 | 106,578 | 3.87% | 3,548,391 | Jun 30, 2024 |
SLATE PATH CAPITAL LP | 4.86% | 0.06% | 2,402,455 | - | - | 2,979,044 | Jun 30, 2024 |
VANGUARD GROUP INC | 4.11% | - | 2,031,421 | -251,941 | -11.03% | 2,518,962 | Jun 30, 2024 |
BLACKROCK INC. | 1.53% | - | 756,736 | -1,487,367 | -66.28% | 938,353 | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 1.00% | 0.00% | 493,987 | 131,897 | 36.43% | 612,544 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 1.00% | 0.00% | 492,456 | -346,075 | -41.27% | 610,794 | Jun 30, 2024 |
ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC | 0.97% | 0.03% | 478,500 | - | - | 593,340 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.71% | 0.00% | 350,419 | -14,763 | -4.04% | 434,519,000 | Jun 30, 2024 |
GOOD LIFE ADVISORS, LLC | 0.66% | 0.03% | 325,000 | 225,000 | 225.00% | 403,001 | Jun 30, 2024 |
GSA CAPITAL PARTNERS LLP | 0.56% | 0.02% | 277,559 | 68,459 | 32.74% | 344,000 | Jun 30, 2024 |
GOLDMAN SACHS GROUP INC | 0.54% | 0.00% | 266,373 | 220,735 | 483.66% | 330,302 | Jun 30, 2024 |
SIGMA PLANNING CORP | 0.54% | 0.01% | 266,030 | 10,025 | 3.92% | 329,877 | Jun 30, 2024 |
ADVISORY RESEARCH INC | 0.52% | 0.06% | 257,225 | - | - | 318,959 | Jun 30, 2024 |
MONACO ASSET MANAGEMENT SAM | 0.51% | 0.05% | 253,185 | -81,557 | -24.36% | 313,949 | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.49% | - | 242,568 | -1,048 | -0.43% | 300,784 | Jun 30, 2024 |
DIMENSIONAL FUND ADVISORS LP | 0.43% | 0.00% | 214,089 | -217,219 | -50.36% | 265,758 | Jun 30, 2024 |
STIFEL FINANCIAL CORP | 0.39% | 0.00% | 193,990 | 1,398 | 0.73% | 240,546 | Jun 30, 2024 |
STATE STREET CORP | 0.36% | - | 177,053 | -582,742 | -76.70% | 219,546,000 | Jun 30, 2024 |
Y-INTERCEPT (HONG KONG) LTD | 0.31% | 0.01% | 153,632 | 153,632 | 100.00% | 190,504 | Jun 30, 2024 |
MORGAN STANLEY | 0.24% | - | 120,999 | -28,877 | -19.27% | 150,039 | Jun 30, 2024 |
Cue Biopharma's largest institutional shareholder is BLEICHROEDER LP, holding 5.78% of the company's total share outstanding, currently valued at $3.55M. The top 10 institutional shareholders own together 21.17% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BLEICHROEDER LP | 5.78% | 1.06% | 2,861,606 | 106,578 | 3.87% | 3,548,391 | Jun 30, 2024 |
DOHENY ASSET MANAGEMENT /CA | 0.03% | 0.18% | 12,660 | 12,660 | 100.00% | 310,000 | Jun 30, 2024 |
ADVISORY RESEARCH INC | 0.52% | 0.06% | 257,225 | - | - | 318,959 | Jun 30, 2024 |
SLATE PATH CAPITAL LP | 4.86% | 0.06% | 2,402,455 | - | - | 2,979,044 | Jun 30, 2024 |
MONACO ASSET MANAGEMENT SAM | 0.51% | 0.05% | 253,185 | -81,557 | -24.36% | 313,949 | Jun 30, 2024 |
GOOD LIFE ADVISORS, LLC | 0.66% | 0.03% | 325,000 | 225,000 | 225.00% | 403,001 | Jun 30, 2024 |
ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC | 0.97% | 0.03% | 478,500 | - | - | 593,340 | Jun 30, 2024 |
GSA CAPITAL PARTNERS LLP | 0.56% | 0.02% | 277,559 | 68,459 | 32.74% | 344,000 | Jun 30, 2024 |
GROUND SWELL CAPITAL, LLC | 0.04% | 0.02% | 18,428 | 18,428 | 100.00% | 22,851 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.11% | 0.01% | 53,027 | 53,027 | 100.00% | 65,753 | Jun 30, 2024 |
SIGMA PLANNING CORP | 0.54% | 0.01% | 266,030 | 10,025 | 3.92% | 329,877 | Jun 30, 2024 |
Y-INTERCEPT (HONG KONG) LTD | 0.31% | 0.01% | 153,632 | 153,632 | 100.00% | 190,504 | Jun 30, 2024 |
NAVALIGN, LLC | 0.05% | 0.01% | 25,000 | - | - | 31,000 | Jun 30, 2024 |
LEGACY CAPITAL GROUP CALIFORNIA, INC. | 0.02% | 0.00% | 10,000 | - | - | 12,400 | Jun 30, 2024 |
BAKER AVENUE ASSET MANAGEMENT, LP | 0.19% | 0.00% | 93,320 | 60,942 | 188.22% | 115,717 | Jun 30, 2024 |
AMERICAN CAPITAL ADVISORY, LLC | 0.00% | 0.00% | 1,000 | - | - | 2,640 | Jun 30, 2024 |
SEACREST WEALTH MANAGEMENT, LLC | 0.03% | 0.00% | 13,000 | - | - | 16,120 | Jun 30, 2024 |
GLEASON GROUP, INC. | 0.01% | 0.00% | 6,000 | - | - | 7,440 | Jun 30, 2024 |
CENTIVA CAPITAL, LP | 0.14% | 0.00% | 66,894 | 66,894 | 100.00% | 82,949 | Jun 30, 2024 |
PALOMA PARTNERS MANAGEMENT CO | 0.07% | 0.00% | 32,595 | 32,595 | 100.00% | 40,418 | Jun 30, 2024 |
The largest Cue Biopharma shareholder by % of total assets is BLEICHROEDER LP. The company owns 2.86M shares of Cue Biopharma (CUE), representing 1.06% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
GOOD LIFE ADVISORS, LLC | 0.66% | 0.03% | 325,000 | 225,000 | 225.00% | 403,001 | Jun 30, 2024 |
GOLDMAN SACHS GROUP INC | 0.54% | 0.00% | 266,373 | 220,735 | 483.66% | 330,302 | Jun 30, 2024 |
Y-INTERCEPT (HONG KONG) LTD | 0.31% | 0.01% | 153,632 | 153,632 | 100.00% | 190,504 | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 1.00% | 0.00% | 493,987 | 131,897 | 36.43% | 612,544 | Jun 30, 2024 |
BLEICHROEDER LP | 5.78% | 1.06% | 2,861,606 | 106,578 | 3.87% | 3,548,391 | Jun 30, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | 0.16% | 0.00% | 80,234 | 80,234 | 100.00% | 99,490 | Jun 30, 2024 |
GSA CAPITAL PARTNERS LLP | 0.56% | 0.02% | 277,559 | 68,459 | 32.74% | 344,000 | Jun 30, 2024 |
CENTIVA CAPITAL, LP | 0.14% | 0.00% | 66,894 | 66,894 | 100.00% | 82,949 | Jun 30, 2024 |
BAKER AVENUE ASSET MANAGEMENT, LP | 0.19% | 0.00% | 93,320 | 60,942 | 188.22% | 115,717 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.11% | 0.01% | 53,027 | 53,027 | 100.00% | 65,753 | Jun 30, 2024 |
HRT FINANCIAL LP | 0.11% | 0.00% | 52,828 | 52,828 | 100.00% | 65,000 | Jun 30, 2024 |
PALOMA PARTNERS MANAGEMENT CO | 0.07% | 0.00% | 32,595 | 32,595 | 100.00% | 40,418 | Jun 30, 2024 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.05% | 0.00% | 24,000 | 24,000 | 100.00% | 29,760 | Jun 30, 2024 |
GROUND SWELL CAPITAL, LLC | 0.04% | 0.02% | 18,428 | 18,428 | 100.00% | 22,851 | Jun 30, 2024 |
MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.04% | 0.00% | 17,897 | 17,897 | 100.00% | 22,192 | Jun 30, 2024 |
DOHENY ASSET MANAGEMENT /CA | 0.03% | 0.18% | 12,660 | 12,660 | 100.00% | 310,000 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.02% | 0.00% | 11,527 | 11,527 | 100.00% | 14,293 | Jun 30, 2024 |
BALYASNY ASSET MANAGEMENT L.P. | 0.02% | - | 10,744 | 10,744 | 100.00% | 13,323 | Jun 30, 2024 |
SIGMA PLANNING CORP | 0.54% | 0.01% | 266,030 | 10,025 | 3.92% | 329,877 | Jun 30, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.02% | 0.00% | 11,381 | 8,113 | 248.26% | 14,113 | Jun 30, 2024 |
As of Jun 30 2024, Cue Biopharma's largest institutional buyer is GOOD LIFE ADVISORS, LLC. The company purchased 225.00K stocks of CUE, valued at $403.00K.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BLACKROCK INC. | 1.53% | - | 756,736 | -1,487,367 | -66.28% | 938,353 | Jun 30, 2024 |
STATE STREET CORP | 0.36% | - | 177,053 | -582,742 | -76.70% | 219,546,000 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 1.00% | 0.00% | 492,456 | -346,075 | -41.27% | 610,794 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -274,033 | -100.00% | - | Jun 30, 2024 |
VANGUARD GROUP INC | 4.11% | - | 2,031,421 | -251,941 | -11.03% | 2,518,962 | Jun 30, 2024 |
DIMENSIONAL FUND ADVISORS LP | 0.43% | 0.00% | 214,089 | -217,219 | -50.36% | 265,758 | Jun 30, 2024 |
NUVEEN ASSET MANAGEMENT, LLC | - | - | - | -146,326 | -100.00% | - | Jun 30, 2024 |
BANK OF NEW YORK MELLON CORP | - | - | - | -92,207 | -100.00% | - | Jun 30, 2024 |
MONACO ASSET MANAGEMENT SAM | 0.51% | 0.05% | 253,185 | -81,557 | -24.36% | 313,949 | Jun 30, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.03% | - | 17,072 | -74,459 | -81.35% | 21,169 | Jun 30, 2024 |
SQUAREPOINT OPS LLC | 0.12% | 0.00% | 57,318 | -58,834 | -50.65% | 71,074 | Jun 30, 2024 |
CORNERCAP INVESTMENT COUNSEL INC | - | - | - | -57,888 | -100.00% | - | Jun 30, 2024 |
WEDMONT PRIVATE CAPITAL | - | - | - | -40,000 | -100.00% | - | Jun 30, 2024 |
UBS GROUP AG | 0.12% | - | 59,016 | -33,951 | -36.52% | 73,180 | Jun 30, 2024 |
DEUTSCHE BANK AG\ | - | - | - | -29,801 | -100.00% | - | Jun 30, 2024 |
OCCUDO QUANTITATIVE STRATEGIES LP | - | - | - | -29,076 | -100.00% | - | Jun 30, 2024 |
MORGAN STANLEY | 0.24% | - | 120,999 | -28,877 | -19.27% | 150,039 | Jun 30, 2024 |
NANTAHALA CAPITAL MANAGEMENT, LLC | - | - | - | -26,692 | -100.00% | - | Jun 30, 2024 |
RHUMBLINE ADVISERS | 0.01% | - | 6,645 | -25,952 | -79.61% | 8,239 | Jun 30, 2024 |
CARLSON CAPITAL L P | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Cue Biopharma's biggest institutional seller is BLACKROCK INC.. The company sold -1.49M shares of CUE, valued at $938.35K.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
Y-INTERCEPT (HONG KONG) LTD | 0.31% | 0.01% | 153,632 | 153,632 | 100.00% | 190,504 | Jun 30, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | 0.16% | 0.00% | 80,234 | 80,234 | 100.00% | 99,490 | Jun 30, 2024 |
CENTIVA CAPITAL, LP | 0.14% | 0.00% | 66,894 | 66,894 | 100.00% | 82,949 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.11% | 0.01% | 53,027 | 53,027 | 100.00% | 65,753 | Jun 30, 2024 |
HRT FINANCIAL LP | 0.11% | 0.00% | 52,828 | 52,828 | 100.00% | 65,000 | Jun 30, 2024 |
PALOMA PARTNERS MANAGEMENT CO | 0.07% | 0.00% | 32,595 | 32,595 | 100.00% | 40,418 | Jun 30, 2024 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.05% | 0.00% | 24,000 | 24,000 | 100.00% | 29,760 | Jun 30, 2024 |
GROUND SWELL CAPITAL, LLC | 0.04% | 0.02% | 18,428 | 18,428 | 100.00% | 22,851 | Jun 30, 2024 |
MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.04% | 0.00% | 17,897 | 17,897 | 100.00% | 22,192 | Jun 30, 2024 |
DOHENY ASSET MANAGEMENT /CA | 0.03% | 0.18% | 12,660 | 12,660 | 100.00% | 310,000 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.02% | 0.00% | 11,527 | 11,527 | 100.00% | 14,293 | Jun 30, 2024 |
BALYASNY ASSET MANAGEMENT L.P. | 0.02% | - | 10,744 | 10,744 | 100.00% | 13,323 | Jun 30, 2024 |
CUBIST SYSTEMATIC STRATEGIES, LLC | 0.01% | - | 4,148 | 4,148 | 100.00% | 5,144 | Jun 30, 2024 |
NEWEDGE ADVISORS, LLC | 0.01% | - | 2,550 | 2,550 | 100.00% | 3,162 | Jun 30, 2024 |
MACQUARIE GROUP LTD | 0.00% | - | 1,805 | 1,805 | 100.00% | 2,238 | Jun 30, 2024 |
SRS CAPITAL ADVISORS, INC. | 0.00% | - | 215 | 215 | 100.00% | 267 | Jun 30, 2024 |
INNEALTA CAPITAL, LLC | 0.00% | - | 49 | 49 | 100.00% | 61 | Jun 30, 2024 |
Cue Biopharma's largest new institutional shareholder by number of shares is Y-INTERCEPT (HONG KONG) LTD, purchased 153.63K shares, valued at $190.50K, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -274,033 | -100.00% | - | Jun 30, 2024 |
NUVEEN ASSET MANAGEMENT, LLC | - | - | - | -146,326 | -100.00% | - | Jun 30, 2024 |
BANK OF NEW YORK MELLON CORP | - | - | - | -92,207 | -100.00% | - | Jun 30, 2024 |
CORNERCAP INVESTMENT COUNSEL INC | - | - | - | -57,888 | -100.00% | - | Jun 30, 2024 |
WEDMONT PRIVATE CAPITAL | - | - | - | -40,000 | -100.00% | - | Jun 30, 2024 |
DEUTSCHE BANK AG\ | - | - | - | -29,801 | -100.00% | - | Jun 30, 2024 |
OCCUDO QUANTITATIVE STRATEGIES LP | - | - | - | -29,076 | -100.00% | - | Jun 30, 2024 |
NANTAHALA CAPITAL MANAGEMENT, LLC | - | - | - | -26,692 | -100.00% | - | Jun 30, 2024 |
CARLSON CAPITAL L P | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -19,974 | -100.00% | - | Jun 30, 2024 |
AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -17,735 | -100.00% | - | Jun 30, 2024 |
INVESCO LTD. | - | - | - | -15,207 | -100.00% | - | Jun 30, 2024 |
VOYA INVESTMENT MANAGEMENT LLC | - | - | - | -13,439 | -100.00% | - | Jun 30, 2024 |
ACADIAN ASSET MANAGEMENT LLC | - | - | - | -12,439 | -100.00% | - | Jun 30, 2024 |
NEW YORK STATE COMMON RETIREMENT FUND | - | - | - | -11,900 | -100.00% | - | Jun 30, 2024 |
SIMPLEX TRADING, LLC | - | - | - | -9,531 | -100.00% | - | Jun 30, 2024 |
LEGAL & GENERAL GROUP PLC | - | - | - | -4,210 | -100.00% | - | Jun 30, 2024 |
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | - | - | - | -3,618 | -100.00% | - | Jun 30, 2024 |
AMERITAS INVESTMENT PARTNERS, INC. | - | - | - | -2,854 | -100.00% | - | Jun 30, 2024 |
AMALGAMATED BANK | - | - | - | -1,165 | -100.00% | - | Jun 30, 2024 |
ROYAL BANK OF CANADA | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
BEAIRD HARRIS WEALTH MANAGEMENT, LLC | - | - | - | -797 | -100.00% | - | Jun 30, 2024 |
NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -7 | -100.00% | - | Jun 30, 2024 |
ASSETMARK, INC | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
Cue Biopharma's largest sold out institutional shareholder by shares sold is RENAISSANCE TECHNOLOGIES LLC, sold -0.27M shares, valued at -, as of undefined.
Cue Biopharma Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
Federated Hermes MDT Series | 0.13% | 313,700 | - | - | Jan 31, 2024 |
VANGUARD VALLEY FORGE FUNDS | 0.05% | 25,288 | - | - | Mar 31, 2024 |
PRUDENTIAL JENNISON BLEND FUND, INC. | 0.05% | 28,909 | - | - | Feb 29, 2024 |
QUANTITATIVE MASTER SERIES LLC | 0.01% | 65,421 | - | - | Mar 31, 2024 |
ETFis Series Trust I | 0.01% | 14,281 | - | - | Jan 31, 2024 |
DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 5,402 | - | - | Mar 31, 2024 |
FORUM FUNDS II | 0.01% | 5,900 | - | - | Jan 31, 2024 |
Nushares ETF Trust | 0.00% | 33,863 | - | - | Jan 31, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 1,944,647 | -441,269 | -18.49% | Mar 31, 2024 |
VANGUARD EXPLORER FUND | 0.00% | 46,345 | - | - | Jan 31, 2024 |
CLEARWATER INVESTMENT TRUST | 0.00% | 33,094 | 33,094 | - | Mar 28, 2024 |
TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 669 | - | - | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 105,691 | 9,611 | 10.00% | Jan 31, 2024 |
Meeder Funds | 0.00% | 10,735 | - | - | Mar 31, 2024 |
Fidelity Commonwealth Trust II | 0.00% | 14,110 | - | - | Aug 31, 2023 |
FIDELITY CONCORD STREET TRUST | 0.00% | 396,295 | 22,465 | 6.01% | Feb 29, 2024 |
ETF Managers Trust | 0.00% | 11,441 | -2,120 | -15.63% | Dec 31, 2023 |
Managed Portfolio Series | 0.00% | 28,405 | - | - | Mar 31, 2024 |
Calvert Variable Products, Inc. | 0.00% | 2,854 | - | - | Mar 31, 2024 |
AMG FUNDS III | 0.00% | 5,087 | - | - | Mar 28, 2024 |
VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 48,489 | -25,438 | -34.41% | Mar 31, 2024 |
SSGA FUNDS | 0.00% | 382 | - | - | Feb 29, 2024 |
FIDELITY COVINGTON TRUST | 0.00% | 15,074 | - | - | Jan 31, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 24,434 | - | - | Mar 31, 2024 |
Federated Hermes Adviser Series | 0.00% | 4,708 | - | - | Mar 31, 2024 |
Direxion Shares ETF Trust | 0.00% | 114,585 | - | - | Jan 31, 2024 |
OHIO NATIONAL FUND INC | 0.00% | 9,963 | - | - | Mar 31, 2024 |
NEW COVENANT FUNDS | 0.00% | 2,087 | - | - | Dec 31, 2023 |
SunAmerica Specialty Series | 0.00% | 237 | - | - | Apr 30, 2021 |
Voya VARIABLE PORTFOLIOS INC | 0.00% | 13,439 | -1,119 | -7.69% | Mar 31, 2024 |
Amplify ETF Trust | 0.00% | 11,612 | 11,612 | - | Mar 31, 2024 |
DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 367,095 | 79,372 | 27.59% | Jan 31, 2024 |
Trust for Advised Portfolios | 0.00% | 7,079 | - | - | Dec 31, 2023 |
TIAA-CREF LIFE FUNDS | 0.00% | 707 | - | - | Mar 31, 2024 |
GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 1,041 | - | - | Mar 31, 2024 |
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,204 | - | - | Mar 31, 2024 |
SCHWAB STRATEGIC TRUST | 0.00% | 124,900 | - | - | Feb 29, 2024 |
HC CAPITAL TRUST | 0.00% | 6,626 | -4,194 | -38.76% | Mar 31, 2024 |
GPS Funds I | 0.00% | 965 | - | - | Mar 31, 2024 |
STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 10,600 | - | - | Mar 31, 2024 |
AdvisorShares Trust | 0.00% | 635 | - | - | Mar 28, 2024 |
VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 1,701 | - | - | Mar 31, 2024 |
NORTHERN FUNDS | 0.00% | 16,002 | -3,023 | -15.89% | Mar 28, 2024 |
T. Rowe Price Index Trust, Inc. | 0.00% | 2,354 | 650 | 38.15% | Mar 31, 2024 |
Forethought Variable Insurance Trust | 0.00% | 434 | - | - | Mar 28, 2024 |
Dimensional ETF Trust | 0.00% | 40,920 | - | - | Jan 31, 2024 |
VANGUARD SCOTTSDALE FUNDS | 0.00% | 162,431 | 25,586 | 18.70% | Feb 29, 2024 |
AMERICAN CENTURY ETF TRUST | 0.00% | 8,875 | -12,971 | -59.37% | Feb 29, 2024 |
iSHARES TRUST | 0.00% | 1,249,076 | -73,256 | -5.54% | Mar 31, 2024 |
RYDEX SERIES FUNDS | 0.00% | 316 | - | - | Dec 31, 2023 |
EQ ADVISORS TRUST | 0.00% | 64,772 | - | - | Mar 31, 2024 |
PENN SERIES FUNDS INC | 0.00% | 1,400 | - | - | Mar 28, 2024 |
VALIC Co I | 0.00% | 13,811 | 494 | 3.71% | Feb 29, 2024 |
TIAA-CREF FUNDS | 0.00% | 146,326 | - | - | Jan 31, 2024 |
RBB FUND, INC. | 0.00% | 4,450 | - | - | Feb 29, 2024 |
NATIONWIDE MUTUAL FUNDS | 0.00% | 5,770 | -40 | -0.69% | Jan 31, 2024 |
COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 45,210 | - | - | Mar 31, 2024 |
FLEXSHARES TRUST | 0.00% | 3,008 | - | - | Jan 31, 2024 |
RYDEX DYNAMIC FUNDS | 0.00% | 156 | - | - | Dec 31, 2023 |
MASTER INVESTMENT PORTFOLIO | 0.00% | 3,329 | - | - | Mar 31, 2024 |
SUNAMERICA SERIES TRUST | 0.00% | 13,677 | 146 | 1.08% | Jan 31, 2024 |
NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 4,925 | - | - | Mar 31, 2024 |
ALLSPRING MASTER TRUST | 0.00% | 2,195 | - | - | Feb 29, 2024 |
Guggenheim Active Allocation Fund | 0.00% | 183 | - | - | Feb 29, 2024 |
ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 1,634 | - | - | Dec 31, 2023 |
FIRST TRUST EXCHANGE-TRADED FUND | 0.00% | 283 | - | - | Mar 31, 2024 |
Pacer Funds Trust | 0.00% | 1,282 | - | - | Jan 31, 2024 |
SPDR SERIES TRUST | 0.00% | 1,011,725 | - | - | Mar 31, 2024 |
ProFunds | 0.00% | 280 | -22 | -7.28% | Mar 31, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 5,624 | 1,029 | 22.39% | Jan 31, 2024 |
PROSHARES TRUST | 0.00% | 5,271 | 809 | 18.13% | Feb 29, 2024 |
RYDEX VARIABLE TRUST | 0.00% | 21 | - | - | Dec 31, 2023 |
MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,488 | - | - | Feb 29, 2024 |
Brighthouse Funds Trust II | 0.00% | 11,773 | - | - | Mar 31, 2024 |
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 31,743 | - | - | Mar 31, 2024 |
ETF Series Solutions | 0.00% | 219 | - | - | Jan 31, 2024 |
iShares U.S. ETF Trust | 0.00% | 904 | - | - | Jan 31, 2024 |
VANGUARD WELLINGTON FUND | 0.00% | 3,004 | - | - | Feb 29, 2024 |
Goldman Sachs ETF Trust | 0.00% | 725 | - | - | Feb 29, 2024 |
Advisors' Inner Circle Fund II | 0.00% | 4,800 | - | - | Jan 31, 2024 |
FIDELITY SALEM STREET TRUST | 0.00% | 17,634 | 2,083 | 13.39% | Mar 31, 2024 |
SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 11,540 | - | - | Dec 31, 2023 |
WILSHIRE MUTUAL FUNDS INC | 0.00% | 940 | - | - | Dec 31, 2023 |
PACIFIC SELECT FUND | 0.00% | 10,522 | - | - | Mar 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 5,565 | 4,901 | 738.10% | Mar 31, 2024 |
Blackstone Alternative Investment Funds | 0.00% | 300 | - | - | Mar 31, 2024 |
MASSMUTUAL SELECT FUNDS | 0.00% | 2,416 | - | - | Dec 31, 2023 |
SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 31,400 | - | - | Feb 29, 2024 |
Bridge Builder Trust | 0.00% | 5,953 | - | - | Mar 31, 2024 |
BlackRock Variable Series Funds, Inc. | 0.00% | 4,136 | - | - | Mar 31, 2024 |
SPDR INDEX SHARES FUNDS | 0.00% | 166 | - | - | Mar 31, 2024 |
PRINCIPAL FUNDS, INC. | 0.00% | 4,525 | 443 | 10.85% | Jan 31, 2024 |
Invesco Exchange-Traded Fund Trust II | 0.00% | 213 | - | - | Jan 31, 2024 |
BLACKROCK FUNDS | 0.00% | 3,595 | - | - | Jan 31, 2024 |
Advisors' Inner Circle Fund III | 0.00% | 39 | - | - | Jan 31, 2024 |
John Hancock Funds II | 0.00% | 3,552 | - | - | Feb 29, 2024 |
VANGUARD WORLD FUND | 0.00% | 52 | - | - | Feb 29, 2024 |
Cue Biopharma's largest mutual fund holder by % of total assets is "Federated Hermes MDT Series", owning 313.70K shares, compromising 0.13% of its total assets.
Cue Biopharma Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 24 | 33 | -58.23% |
31 Mar, 24 | 79 | -7.06% |
31 Dec, 23 | 85 | 7.59% |
30 Sep, 23 | 79 | -1.25% |
30 Jun, 23 | 80 | 25.00% |
31 Mar, 23 | 64 | 1.59% |
31 Dec, 22 | 63 | -1.56% |
30 Sep, 22 | 64 | -16.88% |
30 Jun, 22 | 77 | -27.36% |
31 Mar, 22 | 106 | 10.42% |
31 Dec, 21 | 96 | 3.23% |
30 Sep, 21 | 93 | -1.06% |
30 Jun, 21 | 94 | -1.05% |
31 Mar, 21 | 95 | -6.86% |
31 Dec, 20 | 102 | 7.37% |
30 Sep, 20 | 95 | -5.94% |
30 Jun, 20 | 101 | 34.67% |
31 Mar, 20 | 75 | 19.05% |
31 Dec, 19 | 63 | 43.18% |
30 Sep, 19 | 44 | 22.22% |
30 Jun, 19 | 36 | -2.70% |
31 Mar, 19 | 37 | 5.71% |
31 Dec, 18 | 35 | -2.78% |
30 Sep, 18 | 36 | -7.69% |
30 Jun, 18 | 39 | 34.48% |
31 Mar, 18 | 29 | - |
As of 30 Jun 24, 33 institutions are holding Cue Biopharma's shares, representing a decrease of -58.23% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 24 | 2,353,172 | -85.64% |
31 Mar, 24 | 16,389,056 | 10.09% |
31 Dec, 23 | 14,886,637 | 6.22% |
30 Sep, 23 | 14,014,945 | 1.19% |
30 Jun, 23 | 13,849,912 | 14.89% |
31 Mar, 23 | 12,055,434 | -5.53% |
31 Dec, 22 | 12,761,364 | -0.29% |
30 Sep, 22 | 12,797,936 | -9.15% |
30 Jun, 22 | 14,086,273 | -20.92% |
31 Mar, 22 | 17,813,454 | 7.72% |
31 Dec, 21 | 16,537,180 | -2.11% |
30 Sep, 21 | 16,893,492 | -9.09% |
30 Jun, 21 | 18,582,763 | -1.26% |
31 Mar, 21 | 18,820,469 | -2.56% |
31 Dec, 20 | 19,315,414 | -1.03% |
30 Sep, 20 | 19,516,298 | 21.66% |
30 Jun, 20 | 16,042,181 | 22.72% |
31 Mar, 20 | 13,072,473 | 23.81% |
31 Dec, 19 | 10,558,188 | 73.63% |
30 Sep, 19 | 6,080,917 | 35.09% |
30 Jun, 19 | 4,501,259 | 30.34% |
31 Mar, 19 | 3,453,353 | 6.93% |
31 Dec, 18 | 3,229,523 | -9.79% |
30 Sep, 18 | 3,580,016 | 13.69% |
30 Jun, 18 | 3,148,894 | 70.69% |
31 Mar, 18 | 1,844,804 | - |
Cue Biopharma (CUE) has 2.35M shares outstanding as of 30 Jun 24, down -85.64% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 24 | 4.76% | 0.37% |
31 Mar, 24 | 35.82% | 3.47% |
31 Dec, 23 | 32.11% | 3.28% |
30 Sep, 23 | 31.28% | 3.25% |
30 Jun, 23 | 31.02% | 4.26% |
31 Mar, 23 | 27.00% | 2.11% |
31 Dec, 22 | 35.80% | 2.74% |
30 Sep, 22 | 36.17% | 2.28% |
30 Jun, 22 | 39.84% | 1.34% |
31 Mar, 22 | 54.58% | 1.95% |
31 Dec, 21 | 52.86% | 1.84% |
30 Sep, 21 | 53.60% | 1.51% |
30 Jun, 21 | 59.50% | 1.56% |
31 Mar, 21 | 61.84% | 1.46% |
31 Dec, 20 | 65.14% | 1.50% |
30 Sep, 20 | 65.82% | 2.04% |
30 Jun, 20 | 56.84% | 2.35% |
31 Mar, 20 | 49.20% | 2.14% |
31 Dec, 19 | 47.90% | 6.53% |
30 Sep, 19 | 27.09% | 5.80% |
30 Jun, 19 | 21.62% | 7.78% |
31 Mar, 19 | 16.67% | 6.48% |
31 Dec, 18 | 16.04% | 5.07% |
30 Sep, 18 | 17.78% | 7.27% |
30 Jun, 18 | 15.64% | 18.50% |
31 Mar, 18 | 9.19% | - |
As of 30 Jun 24, Cue Biopharma is held by 4.76% institutional shareholders, representing a 0.37% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 24 | 12 | -47.83% |
31 Mar, 24 | 23 | -37.84% |
31 Dec, 23 | 37 | 8.82% |
30 Sep, 23 | 34 | -34.62% |
30 Jun, 23 | 52 | 116.67% |
31 Mar, 23 | 24 | -11.11% |
31 Dec, 22 | 27 | 58.82% |
30 Sep, 22 | 17 | -58.54% |
30 Jun, 22 | 41 | -18.00% |
31 Mar, 22 | 50 | 2.04% |
31 Dec, 21 | 49 | 32.43% |
30 Sep, 21 | 37 | -7.50% |
30 Jun, 21 | 40 | 5.26% |
31 Mar, 21 | 38 | -29.63% |
31 Dec, 20 | 54 | 8.00% |
30 Sep, 20 | 50 | -29.58% |
30 Jun, 20 | 71 | 69.05% |
31 Mar, 20 | 42 | -12.50% |
31 Dec, 19 | 48 | 54.84% |
30 Sep, 19 | 31 | 34.78% |
30 Jun, 19 | 23 | 64.29% |
31 Mar, 19 | 14 | -12.50% |
31 Dec, 18 | 16 | -15.79% |
30 Sep, 18 | 19 | -36.67% |
30 Jun, 18 | 30 | 3.45% |
31 Mar, 18 | 29 | - |
12 institutional shareholders have increased their position in CUE stock as of 30 Jun 24 compared to 23 in the previous quarter (a -47.83% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 24 | 8 | -71.43% |
31 Mar, 24 | 28 | 47.37% |
31 Dec, 23 | 19 | 18.75% |
30 Sep, 23 | 16 | 77.78% |
30 Jun, 23 | 9 | -47.06% |
31 Mar, 23 | 17 | -5.56% |
31 Dec, 22 | 18 | -41.94% |
30 Sep, 22 | 31 | 34.78% |
30 Jun, 22 | 23 | -14.81% |
31 Mar, 22 | 27 | - |
31 Dec, 21 | 27 | -6.90% |
30 Sep, 21 | 29 | -9.38% |
30 Jun, 21 | 32 | -5.88% |
31 Mar, 21 | 34 | 61.90% |
31 Dec, 20 | 21 | -12.50% |
30 Sep, 20 | 24 | 33.33% |
30 Jun, 20 | 18 | 12.50% |
31 Mar, 20 | 16 | 100.00% |
31 Dec, 19 | 8 | 33.33% |
30 Sep, 19 | 6 | 20.00% |
30 Jun, 19 | 5 | -68.75% |
31 Mar, 19 | 16 | 33.33% |
31 Dec, 18 | 12 | 50.00% |
30 Sep, 18 | 8 | 60.00% |
30 Jun, 18 | 5 | - |
31 Mar, 18 | - | - |
8 institutional shareholders have reduced their position in CUE stock as of 30 Jun 24 compared to 28 in the previous quarter (a -71.43% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 24 | 33 | -58.23% | 2,353,172 | -85.64% | 4.76% | 0.37% | 12 | -47.83% | 8 | -71.43% |
31 Mar, 24 | 79 | -7.06% | 16,389,056 | 10.09% | 35.82% | 3.47% | 23 | -37.84% | 28 | 47.37% |
31 Dec, 23 | 85 | 7.59% | 14,886,637 | 6.22% | 32.11% | 3.28% | 37 | 8.82% | 19 | 18.75% |
30 Sep, 23 | 79 | -1.25% | 14,014,945 | 1.19% | 31.28% | 3.25% | 34 | -34.62% | 16 | 77.78% |
30 Jun, 23 | 80 | 25.00% | 13,849,912 | 14.89% | 31.02% | 4.26% | 52 | 116.67% | 9 | -47.06% |
31 Mar, 23 | 64 | 1.59% | 12,055,434 | -5.53% | 27.00% | 2.11% | 24 | -11.11% | 17 | -5.56% |
31 Dec, 22 | 63 | -1.56% | 12,761,364 | -0.29% | 35.80% | 2.74% | 27 | 58.82% | 18 | -41.94% |
30 Sep, 22 | 64 | -16.88% | 12,797,936 | -9.15% | 36.17% | 2.28% | 17 | -58.54% | 31 | 34.78% |
30 Jun, 22 | 77 | -27.36% | 14,086,273 | -20.92% | 39.84% | 1.34% | 41 | -18.00% | 23 | -14.81% |
31 Mar, 22 | 106 | 10.42% | 17,813,454 | 7.72% | 54.58% | 1.95% | 50 | 2.04% | 27 | - |
31 Dec, 21 | 96 | 3.23% | 16,537,180 | -2.11% | 52.86% | 1.84% | 49 | 32.43% | 27 | -6.90% |
30 Sep, 21 | 93 | -1.06% | 16,893,492 | -9.09% | 53.60% | 1.51% | 37 | -7.50% | 29 | -9.38% |
30 Jun, 21 | 94 | -1.05% | 18,582,763 | -1.26% | 59.50% | 1.56% | 40 | 5.26% | 32 | -5.88% |
31 Mar, 21 | 95 | -6.86% | 18,820,469 | -2.56% | 61.84% | 1.46% | 38 | -29.63% | 34 | 61.90% |
31 Dec, 20 | 102 | 7.37% | 19,315,414 | -1.03% | 65.14% | 1.50% | 54 | 8.00% | 21 | -12.50% |
30 Sep, 20 | 95 | -5.94% | 19,516,298 | 21.66% | 65.82% | 2.04% | 50 | -29.58% | 24 | 33.33% |
30 Jun, 20 | 101 | 34.67% | 16,042,181 | 22.72% | 56.84% | 2.35% | 71 | 69.05% | 18 | 12.50% |
31 Mar, 20 | 75 | 19.05% | 13,072,473 | 23.81% | 49.20% | 2.14% | 42 | -12.50% | 16 | 100.00% |
31 Dec, 19 | 63 | 43.18% | 10,558,188 | 73.63% | 47.90% | 6.53% | 48 | 54.84% | 8 | 33.33% |
30 Sep, 19 | 44 | 22.22% | 6,080,917 | 35.09% | 27.09% | 5.80% | 31 | 34.78% | 6 | 20.00% |
30 Jun, 19 | 36 | -2.70% | 4,501,259 | 30.34% | 21.62% | 7.78% | 23 | 64.29% | 5 | -68.75% |
31 Mar, 19 | 37 | 5.71% | 3,453,353 | 6.93% | 16.67% | 6.48% | 14 | -12.50% | 16 | 33.33% |
31 Dec, 18 | 35 | -2.78% | 3,229,523 | -9.79% | 16.04% | 5.07% | 16 | -15.79% | 12 | 50.00% |
30 Sep, 18 | 36 | -7.69% | 3,580,016 | 13.69% | 17.78% | 7.27% | 19 | -36.67% | 8 | 60.00% |
30 Jun, 18 | 39 | 34.48% | 3,148,894 | 70.69% | 15.64% | 18.50% | 30 | 3.45% | 5 | - |
31 Mar, 18 | 29 | - | 1,844,804 | - | 9.19% | - | 29 | - | - | - |
Cue Biopharma Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
All Insider Owners Trades
The last insider buy of CUE was made by Suri Anish on Aug 29 2023, buying 4,000 shares at $2.76 per share (worth $11.04K).
Cue Biopharma Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | 5 | - | - |
Q1 2024 | 11 | - | - |
Q3 2023 | 7 | - | - |
Q2 2023 | 2 | 1 | 200.00% |
Q1 2023 | 12 | 4 | 300.00% |
Q3 2022 | - | 2 | - |
Q2 2022 | 4 | 2 | 200.00% |
Q1 2022 | 19 | 5 | 380.00% |
Q4 2021 | 8 | 12 | 66.67% |
Q3 2021 | 4 | 6 | 66.67% |
Q1 2021 | 19 | 11 | 172.73% |
Q4 2020 | 2 | 2 | 100.00% |
Q3 2020 | 14 | 17 | 82.35% |
Q2 2020 | 3 | - | - |
Q1 2020 | 16 | 2 | 800.00% |
Q4 2019 | 5 | 11 | 45.45% |
Q2 2019 | 6 | - | - |
Q1 2019 | 17 | - | - |
Q4 2018 | 16 | 1 | 1600.00% |
Q3 2018 | 8 | 2 | 400.00% |
5 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Cue Biopharma's insiders, as of Q2 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | - | - | - |
Q1 2024 | - | - | - |
Q3 2023 | 2 | - | - |
Q2 2023 | - | - | - |
Q1 2023 | - | 1 | - |
Q3 2022 | - | - | - |
Q2 2022 | 3 | - | - |
Q1 2022 | 1 | - | - |
Q4 2021 | - | 5 | - |
Q3 2021 | 1 | 1 | 100.00% |
Q1 2021 | 1 | 5 | 20.00% |
Q4 2020 | 1 | - | - |
Q3 2020 | 2 | 7 | 28.57% |
Q2 2020 | 2 | - | - |
Q1 2020 | - | - | - |
Q4 2019 | - | 7 | - |
Q2 2019 | 6 | - | - |
Q1 2019 | - | - | - |
Q4 2018 | 16 | - | - |
Q3 2018 | 2 | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Cue Biopharma's stocks.
Cue Biopharma Peer Ownership
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
COYA | Coya Therapeutics, Inc. |
TCRX | TScan Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
HOOK | HOOKIPA Pharma Inc. |
FENC | Fennec Pharmaceuticals Inc. |
TERN | Terns Pharmaceuticals, Inc. |
DRMA | Dermata Therapeutics, Inc. |
LTRN | Lantern Pharma Inc. |
TFFP | TFF Pharmaceuticals, Inc. |
INAB | IN8bio, Inc. |
CGTX | Cognition Therapeutics, Inc. |
ANIX | Anixa Biosciences, Inc. |
INMB | INmune Bio, Inc. |
PYPD | PolyPid Ltd. |
GRTX | Galera Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |
CUE Ownership FAQ
Who Owns Cue Biopharma?
Cue Biopharma is owned by institutional shareholders (4.76%), insiders (0.68%), and public (94.56%). The largest institutional shareholder of Cue Biopharma is BLEICHROEDER LP (5.78% of total shares) and the top mutual fund owner is Federated Hermes MDT Series (0.13% of total shares).
Who are the major institutional shareholders of Cue Biopharma?
Cue Biopharma's major institutional shareholders are BLEICHROEDER LP, SLATE PATH CAPITAL LP, VANGUARD GROUP INC, BLACKROCK INC., and MILLENNIUM MANAGEMENT LLC. The top five shareholders own together 17.28% of the company's share outstanding.
How many Cue Biopharma shareholders are there?
As of Jun 2024, there are 33 institutional shareholders of Cue Biopharma.
What percentage of Cue Biopharma is owned by BLEICHROEDER LP?
BLEICHROEDER LP owns 2.86M shares of Cue Biopharma, representing 5.78% of the company's total shares outstanding, valued at $3.55M (as of Jun 2024).
What percentage of Cue Biopharma is owned by SLATE PATH CAPITAL LP?
As of Jun 2024, SLATE PATH CAPITAL LP holds 2.4M shares of Cue Biopharma (CUE), compromising 4.86% of the company, valued at $2.98M.
What percentage of Cue Biopharma is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC is the third largest holder of Cue Biopharma. The company owns 2.03M of the company's shares outstanding (worth $2.52M).